On July 3, 2025, Lantern Pharma Inc. signed an agreement to sell up to $15,530,000 in common stock through ThinkEquity LLC, with a 3% commission on proceeds. The shares will be sold at market prices in an at-the-market offering, and the company has filed a supplementary prospectus with the SEC.